ABBV AbbVie Inc

By Colin Kellaher

AbbVie Inc. on Friday said the U.S. Food and Drug Administration approved the expanded use of its blockbuster psoriasis drug Skyrizi in adults with moderately to severely active Crohn's disease.

The North Chicago, Ill., biopharmaceutical company said Skyrizi is the first new treatment option in six years for moderately to severely active Crohn's, a chronic inflammatory bowel disease.

AbbVie reported worldwide Skyrizi revenue topping $2.9 billion last year and has said it expects risk-adjusted sales of more than $7.5 billion for the drug in 2025.

Skyrizi, which is part of a collaboration between AbbVie and German pharmaceutical company Boehringer Ingelheim GmbH, was previously approved to treat moderate to severe plaque psoriasis and active psoriatic arthritis in adults.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

June 17, 2022 08:32 ET (12:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.